Benzinga
Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. The company has prioritized MT-601 in chimeric antigen receptor (CAR) relapse patients with lymphoma. The FDA cleared Marker's Investigational New Drug application for a Phase 1 trial to investigate MT-601 combined with first-line chemotherapy in patients with pancreatic cancer. The clinical adva
Benzinga